-

- (-%)

Vallon Pharmaceuticals, Inc. [GRI]

Source: 

Company Overview

We are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs. Our clinical-stage product currently under development isAbuse-DeterrentAmphetamineImmediate-Release (ADAIR), a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD), and narcolepsy. It is estimated that over 5million Americans abuse prescription ADHD stimulants annually.

CountryUS
Headquartersla jollacalifornia
Phone Number(619) 400-1171
Industry
CEODavid Baker
Websitevallon-pharma.com.